World News
Business
Investing
Stocks

World News
Business
Investing
Stocks

Home Investing RAD Doses 1st Patient in Therapeutic Trial of 177Lu-RAD202

RAD Doses 1st Patient in Therapeutic Trial of 177Lu-RAD202

RAD Doses 1st Patient in Therapeutic Trial of 177Lu-RAD202

June 4, 2025

Radiopharm Theranostics (RAD:AU) has announced RAD Doses 1st Patient in Therapeutic Trial of 177Lu-RAD202

Download the PDF here.

This post appeared first on investingnews.com

previous post

Triumph Gold Announces the Acquisition of the Coyote Knoll Silver-Gold Mineral Property – Located in Central Utah

next post

Adam Rozencwajg: Gold Stock Gains, Silver and Uranium Prices — Plus PGMs Bull Case

Related Posts

Cygnus secures another two years to increase its...

April 2, 2025

Crypto Market Recap: Institutional Investments, Stablecoin News and...

June 20, 2025

Binding Commitments Received for A$1.0 Million under Convertible...

April 28, 2025

High-Grade Gold Samples extend Clifton East Strike to...

May 22, 2025

Prismo Metals Appoints Gordon Aldcorn as President

June 6, 2025

Spartan Metals

October 22, 2025

Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.

Your name

Your email

By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

Popular

1

First the token, now the swipe: NYC’s subway system to stop selling MetroCards
March 20, 2025
2

AI that can match humans at any task will be here in five to 10 years, Google DeepMind CEO says
March 19, 2025
3

Plummeting stock, boycotts and flagging sales: What’s fueling turmoil for Tesla?
March 18, 2025
4

How new professional sports leagues like SailGP are putting women at the fore
March 21, 2025
5

Lebanon says it was hit by cross-border attack from Syria as tensions escalate
March 18, 2025

About us
Contact us
Privacy Policy
Terms & Conditions

Copyright © 2025 insiderfinancenews.com | All Rights Reserved